Inventia, established in 1985, is a privately held pharmaceutical development and manufacturing company based in mumbai, india. inventia is dedicated to developing complex generic and novel innovative pharmaceutical products, which have been instrumental in enhancing the product portfolio of our partners along with improvement in the patient’s compliance and comfort. we partner with clients across the globe, which ranges from mid-sizes companies to large local players and multi-national companies. by working closely with our clients, we offer an end to end solution - right from research and development all the way to commercialization to support their expansion across emerging and regulated markets. fortified with the ingenuity of a dedicated team of highly skilled scientists, our advanced pharmaceutical and technology centre located at thane, is the heart of inventia where innovative drug delivery systems are developed. our experienced formulation and analytical development teams develop products through a qbd approach. this is made possible on account of our multifunctional dynamic teams that have access to the latest technology and guidelines. our robust intellectual property team enables us to develop non-infringing strategies and file patents for our in-house platform technologies. our highly skilled scale up team transfers the product to our production facility which is equipped with the latest manufacturing equipment’s to ensure a consistent product quality. our dedicated project management teams ensure that we adhere to product timelines and coordinates with multiple departments both within and outside the organization. this helps our regulatory team to file dossiers across the globe. our state of the art pharmaceutical and technology centre is complemented by a world class production facility located at midc ambernath. it is fully compliant with all international regulatory requirements. our manufacturing facility manages the entire product cycle through sap. it has a qc lab with sophisticated equipment that are 21 cfr part ii compliant; stability chambers catering to various climatic zones & state of the art detection & rejection systems. all these ensure consistent product quality across all markets. through this facility, inventia caters to clients present in both emerging and regulated markets. our facility which has capacity of 1 billion units per annum, is approved by several regulatory agencies. some of the global approvals we currently have are: us and europe: us fda, ukmhra latin america: anvisa, cofepris, invima, south east asia/australia/cis: gmp saump, kfda, tga (planned) middle east and africa: fmhaca, ghana fda, jfda, mcaz, nafdac, ppb, tfda, uae moh, uganda nda, mcc (planned). with an ever-growing portfolio of niche products, inventia’s presence has progressively increased to over 50 countries globally. by working closely with our clients, we believe in building and nurturing a long-term trusted relationship - with an aim to be their preferred development and manufacturing partner for any market.